![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (93)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Jordan Dubow, Alon Y Avidan, Bruce Corser, Amod Athavale, David Seiden & Clete Kushida. (2022) Preferences for Attributes of Sodium Oxybate Treatment: A Discrete Choice Experiment in Patients with Narcolepsy. Patient Preference and Adherence 16, pages 937-947.
Read now
Read now
Daniel J. No, Megan S. Inkeles, Mina Amin & Jashin J. Wu. (2018) Drug survival of biologic treatments in psoriasis: a systematic review. Journal of Dermatological Treatment 29:5, pages 460-466.
Read now
Read now
Kristine C Willett & Amanda M Morrill. (2017) Use of direct oral anticoagulants for the prevention and treatment of thromboembolic disease in patients with reduced renal function: a short review of the clinical evidence. Therapeutics and Clinical Risk Management 13, pages 447-454.
Read now
Read now
Walter Ageno, Jan Beyer-Westendorf & Andrea Rubboli. (2017) Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation. Expert Opinion on Pharmacotherapy 18:13, pages 1325-1332.
Read now
Read now
Raj Patel. (2016) Effective management of venous thromboembolism in the community: non-vitamin K antagonist oral anticoagulants. International Journal of General Medicine 9, pages 107-115.
Read now
Read now
Craig I. Coleman, Matthias Antz, Kevin Bowrin, Thomas Evers, Edgar P. Simard, Hendrik Bonnemeier & Riccardo Cappato. (2016) Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study. Current Medical Research and Opinion 32:12, pages 2047-2053.
Read now
Read now
Leon A. Simons, Michael Ortiz, S. Ben Freedman, Benjamin J. Waterhouse, David Colquhoun & Gareth Thomas. (2016) Improved persistence with non-vitamin-K oral anticoagulants compared with warfarin in patients with atrial fibrillation: recent Australian experience. Current Medical Research and Opinion 32:11, pages 1857-1861.
Read now
Read now
José Luis Izquierdo, José Manuel Paredero & Raul Piedra. (2016) Relevance of dosage in adherence to treatment with long-acting anticholinergics in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease 11, pages 289-293.
Read now
Read now
Timothy E Albertson, Richart Harper, Susan Murin & Christian Sandrock. (2015) Patient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol. Patient Preference and Adherence 9, pages 235-242.
Read now
Read now
Paolo Prandoni. (2015) Adherence to the novel oral anticoagulants: an unmet need. Current Medical Research and Opinion 31:12, pages 2175-2177.
Read now
Read now
Winnie W. Nelson, Xue Song, Erin Thomson, David M. Smith, Craig I. Coleman, C.V. Damaraju & Jeffrey R. Schein. (2015) Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrillation. Current Medical Research and Opinion 31:10, pages 1831-1840.
Read now
Read now
Peter P. Toth. (2014) Direct oral anticoagulants as alternative treatment options for the effective long-term treatment of patients with pulmonary embolism in primary care: a review. Annals of Medicine 46:6, pages 341-352.
Read now
Read now
Anna Plitt & Robert P. Giugliano. (2014) Target-Specific Oral Anticoagulants: Practice Issues for the Clinician. Hospital Practice 42:3, pages 48-61.
Read now
Read now
Articles from other publishers (80)
Tsvetelina H. Baryakova, Brett H. Pogostin, Robert Langer & Kevin J. McHugh. (2023) Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. Nature Reviews Drug Discovery 22:5, pages 387-409.
Crossref
Crossref
René Holm, Robert W. Lee, Joey Glassco, Nicholas DiFranco, Quanying Bao, Diane J. Burgess, Viera Lukacova & Simone Alidori. (2023) Long-Acting Injectable Aqueous Suspensions—Summary From an AAPS Workshop. The AAPS Journal 25:3.
Crossref
Crossref
Fiorenzo Santoleri, Luigia Auriemma, Antonella Spacone, Stefano Marinari, Fabio Esposito, Francesco De Vita, Giovanni Petragnani, Caterina Di Fabio, Letizia Di Fabio & Alberto Costantini. (2021) Adherence, Persistence, and Effectiveness in Real Life. Multicenter Long-Term Study on the Use of Pirfenidone and Nintedanib in the Treatment of Idiopathic Pulmonary Fibrosis. Journal of Pharmacy Practice 35:6, pages 853-858.
Crossref
Crossref
Lucas WirbkaCarmen RuffWalter E HaefeliAndreas D Meid. (2022) A prediction model for nonpersistence or nonadherence to direct oral anticoagulants in hospitalized patients with atrial fibrillation. Journal of Managed Care & Specialty Pharmacy 28:10, pages 1161-1172.
Crossref
Crossref
Dirk Kerscher, Sabine Hammer & Michael Jung. (2021) Therapie-Adhärenz bei Patient*innen mit Mukoviszidose im Erwachsenenalter. physioscience 18:03, pages 102-109.
Crossref
Crossref
Elisabeth Smits, Felicita Andreotti, Eline Houben, Harry J. G. M. Crijns, Sylvia Haas, George Spentzouris, Tania Schink, Rosa Gini, Claudia Bartolini, Fernie Penning-van Beest & Ron Herings. (2022) Adherence and Persistence with Once-Daily vs Twice-Daily Direct Oral Anticoagulants Among Patients with Atrial Fibrillation: Real-World Analyses from the Netherlands, Italy and Germany. Drugs - Real World Outcomes 9:2, pages 199-209.
Crossref
Crossref
Xi-Yu Wang, Hung-Yu Chan & Ching-Hua Lin. (2022) Time to Rehospitalization for Different Oral Risperidone Dosing Frequencies in Patients With Schizophrenia. Journal of Clinical Psychopharmacology 42:2, pages 133-139.
Crossref
Crossref
V. A. Sorokoumov. (2022) Anticoagulant therapy for the prevention of recurrent stroke in patients with atrial fibrillation: a comprehensive risk management. Cardiovascular Therapy and Prevention 21:1, pages 3122.
Crossref
Crossref
Max M. Maurer, Marius Ibach, Julius Plewe, Axel Winter, Paul Ritschl, Brigitta Globke, Robert Öllinger, Georg Lurje, Wenzel Schöning, Johann Pratschke & Dennis Eurich. (2022) Reducing the Pill Burden: Immunosuppressant Adherence and Safety after Conversion from a Twice-Daily (IR-Tac) to a Novel Once-Daily (LCP-Tac) Tacrolimus Formulation in 161 Liver Transplant Patients. Biomedicines 10:2, pages 272.
Crossref
Crossref
Sang Hyun Ihm, Kwang-Il Kim, Kyung Jin LeeJong Won WonJin Oh Na, Seung-Woon Rha, Hack-Lyoung Kim, Sang-Hyun Kim & Jinho Shin. (2022) Interventions for Adherence Improvement in the Primary Prevention of Cardiovascular Diseases: Expert Consensus Statement. Korean Circulation Journal 52:1, pages 1.
Crossref
Crossref
Arnar B. Ingason, Jóhann P. Hreinsson, Arnar S. Ágústsson, Sigrún H. Lund, Edward RumbaDaníel A. PálssonIndriði E. ReynissonBrynja R. GuðmundsdóttirPáll T. Önundarson & Einar S. Björnsson. (2021) Rivaroxaban Is Associated With Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants. Annals of Internal Medicine 174:11, pages 1493-1502.
Crossref
Crossref
Walid Al-Qerem, Anan S. Jarab, Mohammad Badinjki, Dana Hyassat & Raghda Qarqaz. (2021) Exploring variables associated with medication non-adherence in patients with type 2 diabetes mellitus. PLOS ONE 16:8, pages e0256666.
Crossref
Crossref
Tsuyoshi Shiga, Toshimi Kimura, Noritoshi Fukushima, Yuji Yoshiyama, Kazunori Iwade, Fumiaki Mori, Yoichi Ajiro, Shoji Haruta, Yuichiro Yamada, Emi Sawada & Nobuhisa Hagiwara. (2021) Electronic monitoring of adherence to once‐daily and twice‐daily direct oral anticoagulants in patients with atrial fibrillation: Baseline data from the SMAAP‐AF trial. Journal of Arrhythmia 37:3, pages 616-625.
Crossref
Crossref
J. Masjuan, J. Gállego, J.M. Aguilera, J.F. Arenillas, M. Castellanos, F. Díaz, J.C. Portilla & F. Purroy. (2021) Use of cardiovascular polypills for the secondary prevention of cerebrovascular disease. Neurología (English Edition) 36:1, pages 1-8.
Crossref
Crossref
J. Masjuan, J. Gállego, J.M. Aguilera, J.F. Arenillas, M. Castellanos, F. Díaz, J.C. Portilla & F. Purroy. (2021) Uso de la polipíldora cardiovascular en la prevención secundaria de la enfermedad cerebrovascular. Neurología 36:1, pages 1-8.
Crossref
Crossref
Ajit Mullasari. (2020) Efficacy and Safety of Ivabradine Once-Daily Prolonged-Release versus Twice-Daily Immediate-Release Formulation in Patients with Stable Chronic Heart Failure with Systolic Dysfunction: A Randomized, Double-Blind, Phase 3 Non-Inferiority (PROFICIENT) Study. Cardiology and Therapy 9:2, pages 505-521.
Crossref
Crossref
V. A. Ionin. (2020) Prevention of thromboembolic complications during cardioversion and catheter ablation in patients with atrial fibrillation: review of key randomized trials. Kardiologiia 60:10, pages 99-106.
Crossref
Crossref
Hime Suzuki, Nobuhiro Mikuni, Hirofumi Ohnishi, Rintaro Yokoyama, Rei Enatsu & Satoko Ochi. (2020) Forgetting to take antiseizure medications is associated with focal to bilateral tonic-clonic seizures, as revealed by a cross-sectional study. PLOS ONE 15:10, pages e0240082.
Crossref
Crossref
Hodaka Yaegashi, So Kirino, Gary Remington, Fuminari Misawa & Hiroyoshi Takeuchi. (2020) Adherence to Oral Antipsychotics Measured by Electronic Adherence Monitoring in Schizophrenia: A Systematic Review and Meta-analysis. CNS Drugs 34:6, pages 579-598.
Crossref
Crossref
Aya F. OzakiAustin S. ChoiQuan T. LeDennis T. KoJanet K. HanSandy S. ParkCynthia A. Jackevicius. (2020) Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes 13:3.
Crossref
Crossref
O. O. KhaniukovL. V. SapozhnychenkoL. V. MeleschykY. S. Balaban. (2020) APPLICATION OF RIVAROXABAN IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: EFFICIENCY, SAFETY AND ADHERENCE TO TREATMENT. Bulletin of Problems Biology and Medicine 4:2, pages 221.
Crossref
Crossref
Jennifer Dotta-Celio, Adriano Alatri, Isabella Locatelli, Monique Salvi, Olivier Bugnon, Marie-Paule Schneider & Lucia Mazzolai. (2019) Patient adherence to rivaroxaban in deep vein thrombosis, a cohort study in Switzerland: quantitative results. International Journal of Clinical Pharmacy 41:6, pages 1625-1633.
Crossref
Crossref
O. D. OstroumovaA. I. Kochetkov, S. P. Korchagina, T. M. OstroumovaM. S. Chernyaeva & A. A. Kirichenko. (2019) Anticoagulant Therapy as a Tool for the Prevention of Cognitive Impairment Associated with Atrial Fibrillation. Rational Pharmacotherapy in Cardiology 15:5, pages 713-724.
Crossref
Crossref
Zh. D. Kobalava, P. V. Lazarev & D. N. Fedorova. (2019) Cognitive Dysfunction at the Background of Atrial Fibrillation: Clinical-Pathological Aspects, Diagnostics and Prevention, Issues of the Use of the Application of Anticoagulant Therapy. Kardiologiia 59:10, pages 66-77.
Crossref
Crossref
Joya D. Pickett. (2019) Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: Update and Periprocedural Management. Critical Care Nurse 39:2, pages 54-67.
Crossref
Crossref
Jin-Kyu Park, Jun Kim, Yong Soo Baek, So-Ryoung Lee, You Mi Hwang, Tae-Hoon Kim, Dae In Lee, Ki Hong Lee, Jaemin Shim & Boyoung Joung. (2019) 2018 KHRS Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Korean Patients with Atrial Fibrillation: How to Initiate and Organize the Follow-up. The Korean Journal of Medicine 94:1, pages 17-39.
Crossref
Crossref
Sai Archana Krovi, Matthew D. Gallovic, Austin M. Keller, Menakshi Bhat, Pamela Tiet, Naihan Chen, Michael A. Collier, Elizabeth G. Gurysh, Erica N. Pino, Monica M. Johnson, M. Shamim Hasan Zahid, Mackenzie L. Cottrell, Jason R. Pirone, Angela D. Kashuba, Jesse J. Kwiek, Eric M. Bachelder & Kristy M. Ainslie. (2018) Injectable long-acting human immunodeficiency virus antiretroviral prodrugs with improved pharmacokinetic profiles. International Journal of Pharmaceutics 552:1-2, pages 371-377.
Crossref
Crossref
G. Denise Zielinski, Martina Teichert, Frederikus A. Klok, Frits R. Rosendaal, Menno V. Huisman, Suzanne C. Cannegieter & Willem M. Lijfering. (2018) Direct oral anticoagulant use and subsequent start of proton pump inhibitors as proxy for gastric complaints. Pharmacoepidemiology and Drug Safety 27:12, pages 1371-1378.
Crossref
Crossref
Yasuo Okumura, Katsuaki Yokoyama, Naoya Matsumoto, Eizo Tachibana, Keiichiro Kuronuma, Koji Oiwa, Michiaki Matsumoto, Toshiaki Kojima, Ken Arima, Tomobumi Kotani, Kazumiki Nomoto, Yukitoshi Ikeya, Seiji Fukushima, Motoyuki Onikura, Yasuko Suzuki, Masami Fujita, Hideyuki Ando, Norikazu Ishikawa & Atsushi Hirayama. (2018) Patient Satisfaction with Direct Oral Anticoagulants and Warfarin. International Heart Journal 59:6, pages 1266-1274.
Crossref
Crossref
A. V. FedoseenkoS. A. ZeninO. V. KononenkoO. V. PyataevaY. E. Voskoboyniokov. (2018) RIVOROXABAN IN PATIENTS WITH TYPE I ATRIAL FLUTTER: EFFECTIVENESS, SAFETY AND COMPLIANCE. Complex Issues of Cardiovascular Diseases 7:3, pages 44-55.
Crossref
Crossref
Tsuyoshi Suzuki, Tsuyoshi Shiga, Hisako Omori, Fujio Tatsumi, Katsuji Nishimura & Nobuhisa Hagiwara. (2018) Self-Reported Non-adherence to Medication in Japanese Patients with Cardiovascular Diseases. American Journal of Cardiovascular Drugs 18:4, pages 311-316.
Crossref
Crossref
A.T. Cohen, G.Y. Lip, R. De Caterina, H. Heidbuchel, J.L. Zamorano, G. Agnelli, F. Verheugt & A.J. Camm. (2018) State of play and future direction with NOACs: An expert consensus. Vascular Pharmacology 106, pages 9-21.
Crossref
Crossref
Elisavet Andrikopoulou, Philip James Scott & Helena Herrera. (2018) Important Design Features of Personal Health Records to Improve Medication Adherence for Patients with Long-Term Conditions: Protocol for a Systematic Literature Review. JMIR Research Protocols 7:6, pages e159.
Crossref
Crossref
R. Kreutz, P.B. Persson, D. Kubitza, K. Thelen, S. Heitmeier, S. Schwers, M. Becka & M. Hemmrich. (2017) Dissociation between the pharmacokinetics and pharmacodynamics of once‐daily rivaroxaban and twice‐daily apixaban: a randomized crossover study. Journal of Thrombosis and Haemostasis 15:10, pages 2017-2028.
Crossref
Crossref
Colleen A. McHorneyVeronica AshtonFrançois LalibertéGuillaume GermainWilly WynantConcetta CriveraJeffrey R. ScheinPatrick LefebvreEric D. Peterson. (2017) Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation. Journal of Managed Care & Specialty Pharmacy 23:9, pages 980-988.
Crossref
Crossref
Tsuyoshi Suzuki, Tsuyoshi Shiga, Hisako Omori, Fujio Tatsumi, Katsuji Nishimura & Nobuhisa Hagiwara. (2017) Adherence to medication and characteristics of Japanese patients with non-valvular atrial fibrillation. Journal of Cardiology 70:3, pages 238-243.
Crossref
Crossref
Tsuyoshi Shiga, Koichiro Yoshioka, Eiichi Watanabe, Hisako Omori, Masahiro Yagi, Yasuo Okumura, Naoki Matsumoto, Kengo Kusano, Chikara Oshiro, Takanori Ikeda, Naohiko Takahashi, Takashi Komatsu, Atsushi Suzuki, Tsuyoshi Suzuki, Yasuto Sato & Takeshi Yamashita. (2017) Paroxysmal atrial fibrillation recurrences and quality of life in symptomatic patients: A crossover study of flecainide and pilsicainide. Journal of Arrhythmia 33:4, pages 310-317.
Crossref
Crossref
Carly M. Goldstein, Emily C. Gathright, John Gunstad, Mary A. Dolansky, Joseph D. Redle, Richard Josephson, Shirley M. Moore & Joel W. Hughes. (2017) Depressive symptoms moderate the relationship between medication regimen complexity and objectively measured medication adherence in adults with heart failure. Journal of Behavioral Medicine 40:4, pages 602-611.
Crossref
Crossref
Jaclyn K. Schwartz & Roger O. Smith. (2017) Integration of Medication Management Into Occupational Therapy Practice. The American Journal of Occupational Therapy 71:4, pages 7104360010p1-7104360010p7.
Crossref
Crossref
Emilie R. Elliot, Alieu Amara, Nicole Pagani, Laura Else, Graeme Moyle, Alex Schoolmeesters, Chris Higgs, Saye Khoo & Marta Boffito. (2017) Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge. Journal of Antimicrobial Chemotherapy 72:7, pages 2035-2041.
Crossref
Crossref
Melvin Lafeber, Wilko Spiering, Frank LJ Visseren, Diederick E Grobbee, Michiel L Bots, Alice Stanton, Anushka Patel, Dorairaj Prabhakaran, Ruth Webster, Simon Thom & Anthony Rodgers. (2017) Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk. European Journal of Preventive Cardiology 24:9, pages 951-961.
Crossref
Crossref
Lingyun Lu, Cynthia A. Jackevicius, Noelle K. de Leon, Alberta L. Warner, Donald S. Chang & Freny Vaghaiwalla Mody. (2017) Impact of a Multidisciplinary Heart Failure Postdischarge Management Clinic on Medication Adherence. Clinical Therapeutics 39:6, pages 1200-1209.
Crossref
Crossref
Ondřej Ludka. (2017) Patient motivation for lifelong use of antihypertensive medication. Medicína pro praxi 14:1, pages 11-14.
Crossref
Crossref
U. Christmann & C. Pink. (2017) Lessons learned from a strangles outbreak on a large Standardbred farm. Equine Veterinary Education 29:3, pages 138-143.
Crossref
Crossref
Johannes C. von Alvensleben, Martin J. LaPage, Regine Caruthers & David J. Bradley. (2016) Nadolol for Treatment of Supraventricular Tachycardia in Infants and Young Children. Pediatric Cardiology 38:3, pages 525-530.
Crossref
Crossref
José Ramón González-Juanatey, José María Mostaza, José María Lobos, Benjamín Abarca, José Luis Llisterri, Gonzalo Baron-Esquivias, Enrique Galve, Rosa María Lidón, Francisco Xavier Garcia-Moll, Pedro Luis Sánchez, Carmen Suárez, Jesús Millán, Vicente Pallares, José Juan Alemán & Isabel Egocheaga. (2017) Documento de consenso del uso clínico de la Polypill en la prevención secundaria del riesgo cardiovascular. Medicina Clínica 148:3, pages 139.e1-139.e15.
Crossref
Crossref
José Ramón González-Juanatey, José María Mostaza, José María Lobos, Benjamín Abarca, José Luis Llisterri, Gonzalo Baron-Esquivias, Enrique Galve, Rosa María Lidón, Francisco Xavier Garcia-Moll, Pedro Luis Sánchez, Carmen Suárez, Jesús Millán, Vicente Pallares, José Juan Alemán & Isabel Egocheaga. (2017) Consensus document for the use of the Polypill in the secondary prevention of cardiovascular disease. Medicina Clínica (English Edition) 148:3, pages 139.e1-139.e15.
Crossref
Crossref
Thomas Wilke, Sabine Bauer, Sabrina Mueller, Thomas Kohlmann & Rupert Bauersachs. (2016) Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature Review. The Patient - Patient-Centered Outcomes Research 10:1, pages 17-37.
Crossref
Crossref
Andreas Goette & Matthias Hammwöhner. (2016) How important it is for therapy adherence to be once a day?. European Heart Journal Supplements 18:suppl I, pages I7-I12.
Crossref
Crossref
Alpesh Amin & Joel C. Marrs. (2016) Direct Oral Anticoagulants for the Management of Thromboembolic Disorders. Clinical and Applied Thrombosis/Hemostasis 22:7, pages 605-616.
Crossref
Crossref
Craig I. Coleman, Sylvia Haas, Alexander G.G. Turpie, Silvia Kuhls, Susanne Hess, Thomas Evers, Pierre Amarenco, Paulus Kirchhof & A. John Camm. (2016) Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS-ACTS Substudy. Clinical Cardiology 39:10, pages 565-569.
Crossref
Crossref
Dagmar Kubitza, Scott D. Berkowitz & Frank Misselwitz. (2016) Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications. Clinical and Applied Thrombosis/Hemostasis 22:5, pages 412-422.
Crossref
Crossref
Craig I. Coleman, Muralikrishna Tangirala & Thomas Evers. (2016) Medication adherence to rivaroxaban and dabigatran for stroke prevention in patients with non-valvular atrial fibrillation in the United States. International Journal of Cardiology 212, pages 171-173.
Crossref
Crossref
Emilie Elliot, Alieu Amara, Akil Jackson, Graeme Moyle, Laura Else, Saye Khoo, David Back, Andrew Owen & Marta Boffito. (2016) Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake. Journal of Antimicrobial Chemotherapy 71:4, pages 1031-1036.
Crossref
Crossref
Walid Amara & Sotiris Antoniou. (2016) Benefits of once-daily dosing with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal Supplements 18:suppl D, pages D1-D6.
Crossref
Crossref
Milica Zeković, Dušanka Krajnović, Valentina Marinković & Ljiljana Tasić. (2016) THE COMPLEXITY OF ADHERENCE ISSUE: A REVIEW OF ITS SCOPE AND DETERMINANTS. Acta Medica Medianae 55:1, pages 51-58.
Crossref
Crossref
Björn Böttger, Inga-Marion Thate-Waschke, Rupert Bauersachs, Thomas Kohlmann & Thomas Wilke. (2015) Preferences for anticoagulation therapy in atrial fibrillation: the patients’ view. Journal of Thrombosis and Thrombolysis 40:4, pages 406-415.
Crossref
Crossref
Hein Heidbuchel & Bernard Vrijens. (2015) Non-vitamin K antagonist oral anticoagulants (NOAC): considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace 17:8, pages 1317-1318.
Crossref
Crossref
William L. Baker & Craig I. Coleman. (2015) Medication adherence and non-vitamin K antagonist oral anticoagulants: what do we really know?. Europace 17:8, pages 1316.2-1317.
Crossref
Crossref
Marcel Adler & Michael Nagler. (2015) Adherence to treatment with non-vitamin K antagonist anticoagulants: once- vs. twice-daily regimens. Europace 17:8, pages 1316.1-1316.
Crossref
Crossref
Kristy Iglay, Xiting Cao, Panagiotis Mavros, Kruti Joshi, Shengsheng Yu & Kaan Tunceli. (2015) Systematic Literature Review and Meta-analysis of Medication Adherence With Once-weekly Versus Once-daily Therapy. Clinical Therapeutics 37:8, pages 1813-1821.e1.
Crossref
Crossref
David A. Margolis & Marta Boffito. (2015) Long-acting antiviral agents for HIV treatment. Current Opinion in HIV and AIDS 10:4, pages 246-252.
Crossref
Crossref
Margaret Irwin & Lee Ann Johnson. (2015) Factors Influencing Oral Adherence: Qualitative Metasummary and Triangulation With Quantitative Evidence. Clinical Journal of Oncology Nursing 19:3, pages 6-30.
Crossref
Crossref
Nicoletta Riva, Christian Borg Xuereb & Walter Ageno. (2015) Anticoagulant therapy in atrial fibrillation. Journal of Cardiovascular Medicine 16:2, pages 139-141.
Crossref
Crossref
M. Lafeber, D.E. Grobbee, I.M. Schrover, S. Thom, R. Webster, A. Rodgers, F.L.J. Visseren, M.L. Bots & W. Spiering. (2015) Comparison of a morning polypill, evening polypill and individual pills on LDL-cholesterol, ambulatory blood pressure and adherence in high-risk patients; a randomized crossover trial. International Journal of Cardiology 181, pages 193-199.
Crossref
Crossref
Yohei OHASHI, Yuki MIYAMOTO & Kazuma IEKUSHI. (2015) Clinical development of novel oral anticoagulant (NOAC), Rivaroxaban. Japanese Journal of Thrombosis and Hemostasis 26:4, pages 385-395.
Crossref
Crossref
Sebastian M. Stricker, Kathleen A. Fox, Rachel Baggaley, Eyerusalem Negussie, Saskia de Pee, Nils Grede & Martin W. Bloem. (2013) Retention in Care and Adherence to ART are Critical Elements of HIV Care Interventions. AIDS and Behavior 18:S5, pages 465-475.
Crossref
Crossref
R. Faria, M. Barbieri, K. Light, R. A. Elliott & M. Sculpher. (2014) The economics of medicines optimization: policy developments, remaining challenges and research priorities. British Medical Bulletin 111:1, pages 45-61.
Crossref
Crossref
Reinhold Kreutz. (2013) A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban. Journal of Thrombosis and Thrombolysis 38:2, pages 137-149.
Crossref
Crossref
Daniel Caldeira, António Vaz-Carneiro & João Costa. (2014) The impact of dosing frequency on medication adherence in chronic cardiovascular disease: Systematic review and meta-analysis. Revista Portuguesa de Cardiologia (English Edition) 33:7-8, pages 431-437.
Crossref
Crossref
Daniel Caldeira, António Vaz‐Carneiro & João Costa. (2014) Impacto da frequência posológica na adesão terapêutica em doenças cardiovasculares crónicas: revisão sistemática e meta‐análise. Revista Portuguesa de Cardiologia 33:7-8, pages 431-437.
Crossref
Crossref
Bernard Vrijens, Marc J. Claeys, Victor Legrand, Eef Vandendriessche & Frans Van de Werf. (2014)
Projected inhibition of platelet aggregation with ticagrelor twice daily
vs.
clopidogrel once daily based on patient adherence data (the TWICE project)
. British Journal of Clinical Pharmacology 77:5, pages 746-755.
Crossref
Crossref
Alessandro Di Minno, Gaia Spadarella, Antonella Tufano, Domenico Prisco & Giovanni Di Minno. (2014) Ensuring medication adherence with direct oral anticoagulant drugs. Thrombosis Research 133:5, pages 699-704.
Crossref
Crossref
Rita R. Alloway, Devin E. Eckhoff, W. Kenneth Washburn & Lewis W. Teperman. (2014) Conversion from twice daily tacrolimus capsules to once daily extended‐release tacrolimus (LCP‐Tacro): Phase 2 trial of stable liver transplant recipients. Liver Transplantation 20:5, pages 564-575.
Crossref
Crossref
Kathy J. Wheeler, Mary Ellen Roberts & Mary B. Neiheisel. (2014) Medication adherence part two: Predictors of nonadherence and adherence. Journal of the American Association of Nurse Practitioners 26:4, pages 225-232.
Crossref
Crossref
Marta Boffito, Akil Jackson, Andrew Owen & Stephen Becker. (2013) New Approaches to Antiretroviral Drug Delivery: Challenges and Opportunities Associated with the Use of Long-Acting Injectable Agents. Drugs 74:1, pages 7-13.
Crossref
Crossref
Irene Savelieva & A. John Camm. (2014) Practical Considerations for Using Novel Oral Anticoagulants in Patients With Atrial Fibrillation. Clinical Cardiology 37:1, pages 32-47.
Crossref
Crossref
Giulia Renda & Raffaele De Caterina. (2013) The new oral anticoagulants in atrial fibrillation: Once daily or twice daily?. Vascular Pharmacology 59:3-4, pages 53-62.
Crossref
Crossref
Melvin Lafeber, Wilko Spiering, Yolanda van der Graaf, Hendrik Nathoe, Michiel L. Bots, Diederick E. Grobbee & Frank L.J. Visseren. (2013) The combined use of aspirin, a statin, and blood pressure–lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease. American Heart Journal 166:2, pages 282-289.e1.
Crossref
Crossref
Troy C. Sarich, Gary Peters, Scott D. Berkowitz, Frank Misselwitz, Christopher C. Nessel, Paul Burton, Nancy Cook-Bruns, Anthonie W.A. Lensing, Lloyd Haskell, Elisabeth Perzborn, Dagmar Kubitza, Kenneth T. Moore, Sanjay Jalota, Juergen Weber, Guohua Pan, Xiang Sun, Torsten Westermeier, Andrea Nadel, Leonard Oppenheimer & Peter M. DiBattiste. (2013) Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions. Annals of the New York Academy of Sciences 1291:1, pages 42-55.
Crossref
Crossref